Epigenetic Modifiers in Cancer Metastasis

被引:2
|
作者
Hu, Die [1 ,2 ,3 ]
Zhao, Tianci [4 ,5 ]
Xu, Chenxing [3 ]
Pan, Xinyi [3 ]
Zhou, Zhengyu [1 ,2 ,6 ]
Wang, Shengjie [1 ,2 ,3 ,6 ]
机构
[1] Nanjing Med Univ, Kangda Coll, Key Lab Mol Genet, Suzhou 215123, Peoples R China
[2] Soochow Univ, Suzhou Med Coll, Key Lab Mol Genet, Suzhou 215123, Peoples R China
[3] Nanjing Med Univ, Kangda Coll, Dept Basic Med, Lianyungang 222000, Peoples R China
[4] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110122, Peoples R China
[5] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110122, Peoples R China
[6] Soochow Univ, Suzhou Med Coll, Lab Anim Ctr, Suzhou 215123, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
epigenetics; DNA methylation; histone methylation; non-coding RNAs; metastasis; ENHANCER REPROGRAMMING PROMOTES; BREAST-CANCER; NONCODING RNA; LUNG METASTASIS; MESSENGER-RNA; LIVER-DISEASE; CELL; METHYLATION; GROWTH; CHROMATIN;
D O I
10.3390/biom14080916
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metastasis is the primary cause of cancer-related death, with the dissemination and colonization of primary tumor cells at the metastatic site facilitated by various molecules and complex pathways. Understanding the biological mechanisms underlying the metastatic process is critical for the development of effective interventions. Several epigenetic modifications have been identified that play critical roles in regulating cancer metastasis. This review aims to provide a comprehensive summary of recent advances in understanding the role of epigenetic modifiers, including histone modifications, DNA methylation, non-coding RNAs, enhancer reprogramming, chromatin accessibility, and N6-methyladenosine, in metastasis-associated processes, such as epithelial-mesenchymal transition (EMT), cancer cell migration, and invasion. In particular, this review provides a detailed and in-depth description of the role of crosstalk between epigenetic regulators in tumor metastasis. Additionally, we explored the potential and limitations of epigenetics-related target molecules in the diagnosis, treatment, and prognosis of cancer metastasis.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Targeting epigenetic modifiers in cancer
    Holloway, A. F.
    Oakford, P. C.
    CURRENT MEDICINAL CHEMISTRY, 2007, 14 (24) : 2540 - 2547
  • [2] Targeting Epigenetic Modifiers for Cancer Treatments
    Chee C.S.
    Leung D.
    Current Pharmacology Reports, 2018, 4 (3) : 193 - 201
  • [3] MicroRNA Regulation of Epigenetic Modifiers in Breast Cancer
    Humphries, Brock
    Wang, Zhishan
    Yang, Chengfeng
    CANCERS, 2019, 11 (07)
  • [4] Key actors in cancer therapy: epigenetic modifiers
    Akar, Remzi Okan
    Selvi, Selin
    Ulukaya, Engin
    Aztopal, Nazlihan
    TURKISH JOURNAL OF BIOLOGY, 2019, 43 (03) : 155 - 170
  • [5] Epigenetic contributions to cancer metastasis
    David I. Rodenhiser
    Clinical & Experimental Metastasis, 2009, 26 : 5 - 18
  • [6] Epigenetic contributions to cancer metastasis
    Rodenhiser, David I.
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (01) : 5 - 18
  • [7] Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
    Feinberg, Andrew P.
    Koldobskiy, Michael A.
    Gondor, Anita
    NATURE REVIEWS GENETICS, 2016, 17 (05) : 284 - 299
  • [8] Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges
    Shankar, Eswar
    Kanwal, Rajnee
    Candamo, Mario
    Gupta, Sanjay
    SEMINARS IN CANCER BIOLOGY, 2016, 40-41 : 82 - 99
  • [9] The application of epigenetic modifiers on the treatment of prostate and bladder cancer
    Zhang, ZW
    Karam, J
    Frenkel, E
    Sagalowsky, A
    Hsieh, JT
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (02) : 152 - 160
  • [10] MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review
    Favier, Amelia
    Rocher, Gregoire
    Larsen, Annette K.
    Delangle, Romain
    Uzan, Catherine
    Sabbah, Michele
    Castela, Mathieu
    Duval, Alex
    Mehats, Celine
    Canlorbe, Geoffroy
    CANCERS, 2021, 13 (05) : 1 - 35